Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer.

Oncoimmunology - 31 Dec 2025

Ruiz-Lorente Inmaculada, Gimeno Lourdes, López-Abad Alicia, Cubillana Pedro López, Aparicio Tomás Fernández, Egea Lucas Jesús Asensio, Avilés Juan Moreno, Iñiguez Gloria Doñate, Martínez-Valls Pablo Luis Guzmán, Server Gerardo, Ferri Belén, Campillo José Antonio, Galindo Francisco, Martínez-Sánchez María Victoria, Minguela Alfredo

Abstract excerpt

Bacille Calmette-Guerin (BCG) is the immunotherapy of choice for high-risk non-muscle invasive bladder cancer (BC), although recurrence eventually occurs in 50% of patients and 20% progress to advanced stages. This study evaluates the predictive value of human leukocyte antigen class-I (HLA-I) genotyping to guide BCG immunotherapy. HLA-I genotyping and expression of NK cell receptors in circulating T and NK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to BCG Vaccine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytokines

Share to Histocompatibility Antigens Class I

Share to Immunotherapy

Share to Killer Cells, Natural

Share to Precision Medicine

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41384865
DOI: 10.1080/2162402X.2025.2598920
PMCID: PMC12710922

Genes

KIR3DL1
CD226
CD28

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer.PMID 41384865Read ↗

Differential Role of NKG2A/Hla-E Interaction in the Outcome of Bladder Cancer Patients Treated with M. bovis Bcg or Other TherapiesSemantic proximity Read ↗

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.Semantic proximity Read ↗

The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population.Semantic proximity Read ↗

Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomesSemantic proximity Read ↗

Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.Semantic proximity Read ↗

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Cell therapy could benefit from BCG: how anti-tumour BCG-primed NK cells selectively proliferate over other lymphocytes and efficiently kill cancer cellsSemantic proximity Read ↗

Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer.Semantic proximity Read ↗

NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor OutcomeSemantic proximity Read ↗

Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.Semantic proximity Read ↗

Increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages associate with poor clinical outcomes in BCG treated non-muscle invasive bladder cancerSemantic proximity Read ↗

The Role of Vitamin D Receptor Polymorphisms in Predicting the Response to Therapy for Nonmuscle Invasive Bladder Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.